Program
islatravir
Also written as “DOR/ISL”, “Islatravir” and “ISL”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Infections, led by 2 companies.
Drug pageIslatravir: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 277 open or running | phase 3since Jan 8, 2020 | Aug 13, 2014 | Aug 10, 2027phase 2 · NCT06891066 |
| Gilead Sciencesits history only | 11 open or running | phase 2since Sep 13, 2021 | Sep 13, 2021 | none ahead |
- Named in Merck’s own pipeline as
islatravir + lenacapavir (MK-8591D)
, phase 3, as of Nov 2, 2026 (source). - Named in Merck’s own pipeline as
islatravir + ulonivirine (MK-8591B)
, phase 2, as of Nov 2, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 11 earlier studies, Aug 13, 2014 to Sep 21, 2020.
- Dec 9, 2018Named islatravirINNProposed as its International Nonproprietary Name in WHO's List 120
- Sep 23, 2020Phase 1 study in HIV-1 InfectionNCT04568603 · 14 enrolled · United States
- Nov 23, 2020Phase 3 study in Acquired Immunodeficiency SyndromeNCT04644029 · 730 enrolled · United States, South Africa, Uganda
- Dec 2, 2020Phase 3 study in HIV Preexposure ProphylaxisNCT04652700 · 494 enrolled · United States, Brazil, France and more
- Nov 2, 20212 phase 2 studies in Acquired Immunodeficiency SyndromeNCT05115838, NCT05130086
- Nov 18, 20222 phase 3 studies in HIV-1 InfectionNCT05631093, NCT05630755
- Jan 20, 2023Phase 3 study in HIV-1 InfectionNCT05705349 · 537 enrolled · United States, Argentina, Canada and more
- Mar 1, 2023Phase 3 study in HIV InfectionsNCT05766501 · 641 enrolled · United States, Argentina, Australia and more
- Sep 27, 2024Phase 1 study in HealthyNCT06619678 · 36 enrolled · United States
- Dec 2, 2024Phase 1 study in HealthyNCT06719570 · 24 enrolled · United States
- Jan 31, 2025Phase 1 study in HealthyNCT06811246 · 20 enrolled · United States
- Mar 17, 2025Phase 2 study in Acquired Immunodeficiency SyndromeNCT06891066 · 150 enrolled · United States, Australia, Puerto Rico and more
- Jul 18, 2025Phase 1 study in HealthyNCT07086079 · 12 enrolled · United States
- Dec 1, 2025Phase 3 study in Acquired Immunodeficiency SyndromeNCT07266831 · 570 planned · United States, Argentina, Canada and more
- Oct 2, 2026Phase 2 study in HIV InfectionsNCT07862569 · 45 planned · United States
Ahead
- Aug 10, 2027Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeNCT06891066
- Feb 1, 2029Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeNCT07266831
- Sep 24, 2029Primary completion: phase 2 study in HIV InfectionsNCT07862569
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 27 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07862569HIV Infections · United States | 2 | Not yet recruiting | Sep 24, 2029 | 45 |
| NCT07266831Acquired Immunodeficiency Syndrome · United States, Argentina, Canada and more | 3 | Recruiting | Feb 1, 2029 | 570 |
| NCT07086079Healthy · United States | 1 | Completed | Dec 8, 2025 | 12 |
| NCT06891066Acquired Immunodeficiency Syndrome · United States, Australia, Puerto Rico and more | 2 | Active, not recruiting | Aug 10, 2027 | 150 |
| NCT06811246Healthy · United States | 1 | Completed | Jul 14, 2024 | 20 |
| NCT06719570Healthy · United States | 1 | Completed | Mar 15, 2024 | 24 |
| NCT06619678Healthy · United States | 1 | Completed | Jun 23, 2024 | 36 |
| NCT05766501HIV Infections · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 16, 2025 | 641 |
| NCT05705349HIV-1 Infection · United States, Argentina, Canada and more | 3 | Active, not recruiting | Oct 13, 2025 | 537 |
| NCT05631093HIV-1 Infection · United States, Australia, Canada and more | 3 | Active, not recruiting | Oct 10, 2024 | 553 |
| NCT05630755HIV-1 Infection · United States, Australia, Chile and more | 3 | Active, not recruiting | Oct 25, 2024 | 514 |
| NCT05130086Acquired Immunodeficiency Syndrome | 2 | Withdrawn | Mar 25, 2024 | 0 |
| NCT05115838Acquired Immunodeficiency Syndrome | 2 | Withdrawn | Oct 2, 2025 | 0 |
| NCT04652700HIV Preexposure Prophylaxis · United States, Brazil, France and more | 3 | Terminated | Aug 4, 2023 | 494 |
| NCT04644029Acquired Immunodeficiency Syndrome · United States, South Africa, Uganda | 3 | Terminated | Jul 18, 2023 | 730 |
| NCT04568603HIV-1 Infection · United States | 1 | Completed | Jul 9, 2021 | 14 |
| NCT04564547HIV-1 Infection · United States, France, Switzerland | 2 | Completed | Jan 30, 2025 | 161 |
| NCT04515641Acquired Immunodeficiency Syndrome · United States | 1 | Completed | Sep 13, 2021 | 12 |
| NCT04303156Acquired Immunodeficiency Syndrome · United States, Germany | 1 | Completed | Oct 19, 2020 | 12 |
| NCT04295772HIV-1 Infection · United States, Italy, Russian Federation and more | 2 | Completed | Dec 21, 2021 | 42 |
| NCT04233879HIV-1 Infection · United States, Argentina, Canada and more | 3 | Completed | Nov 17, 2022 | 599 |
| NCT04233216HIV-1 Infection · United States, Australia, Canada and more | 3 | Completed | Nov 21, 2022 | 35 |
| NCT04223791HIV Infections · United States, Australia, Austria and more | 3 | Completed | Aug 26, 2021 | 643 |
| NCT04223778HIV Infections · United States, Australia, Canada and more | 3 | Completed | Sep 8, 2021 | 672 |
| NCT04003103HIV-1 Infection · United States, Israel, South Africa | 2 | Completed | Mar 18, 2022 | 242 |
| NCT03272347HIV-1 Infection · United States, Chile, France and more | 2 | Completed | Mar 8, 2021 | 123 |
| NCT02217904HIV-1 | 1 | Completed | May 11, 2017 | 30 |
How it is read
Names in the registry
- “DOR/ISL”, 11 entries
- “Islatravir”, 11 entries
- “ISL”, 5 entries
- “Islatravir (ISL)”, 1 entry
- “Doravirine/Islatravir”, 1 entry
Conditions, from the studies’ own filings
- HIV Infections, 4 studies
- Acquired Immunodeficiency Syndrome, 4 studies
- Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.